Compare · AZN vs LVTX
AZN vs LVTX
Side-by-side comparison of AstraZeneca PLC (AZN) and LAVA Therapeutics N.V. (LVTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and LVTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $257.64B, about 1766.0x LVTX ($145.9M).
- Over the past year, AZN is down 11.8% and LVTX is up 11.5% - LVTX leads by 23.3 points.
- AZN has hit the wire 30 times in the past 4 weeks while LVTX has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 5 for LVTX).
- Company
- AstraZeneca PLC
- LAVA Therapeutics N.V.
- Price
- $166.13+1.99%
- $1.65-8.84%
- Market cap
- $257.64B
- $145.9M
- 1M return
- +3.77%
- +1.85%
- 1Y return
- -11.77%
- +11.49%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2021
- News (4w)
- 30
- 0
- Recent ratings
- 25
- 5
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
LAVA Therapeutics N.V.
Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Latest AZN
- Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca upgraded by Deutsche Bank
- SEC Form 6-K filed by AstraZeneca PLC
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
- Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
- Officer Sharma Mani bought $3,249 worth of Ordinary Shares (20 units at $160.57) and was granted 1 units of Ordinary Shares, increasing direct ownership by 0.11% to 19,289 units (SEC Form 4)
Latest LVTX
- Amendment: SEC Form 25-NSE/A filed by LAVA Therapeutics N.V.
- SEC Form S-8 POS filed by LAVA Therapeutics N.V.
- SEC Form S-8 POS filed by LAVA Therapeutics N.V.
- Amendment: SEC Form SC 14D9/A filed by LAVA Therapeutics N.V.
- LAVA Therapeutics N.V. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Leadership Update
- Amendment: SEC Form SC TO-T/A filed by LAVA Therapeutics N.V.
- XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
- Chief Financial Officer Powell Fred M returned 65,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Oliger Christy J.
- SEC Form 4 filed by Director Wadlinger Mary E.